Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IFIN Stock Forecast 2026-2027
$3.11
Current Price
$41.18M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IFIN Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
IFIN Price Momentum
-1.0%
1 Week Change
-19.8%
1 Month Change
+522.0%
1 Year Change
+73.7%
Year-to-Date Change
-34.2%
From 52W High of $4.73
+851.7%
From 52W Low of $0.33
📊 TOP ANALYST CALLS
Did IFIN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if InFinT is one of their latest high-conviction picks.
Latest IFIN Stock Price Targets & Analyst Predictions
IFIN has shown a year-to-date change of 73.7% and a 1-year change of 522.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for IFIN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IFIN Analyst Ratings
0
Buy
0
Hold
0
Sell
IFIN Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.11
Latest IFIN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IFIN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Cure Pharmaceutical Holding Corp. (IFIN) Competitors
The following stocks are similar to InFinT based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cure Pharmaceutical Holding Corp. (IFIN) Financial Data
Valuation Metrics
Market Cap
$41.18M
Enterprise Value
$0
P/E Ratio
36.9x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.0%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
+4.3%
ROA
+3.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cure Pharmaceutical Holding Corp. (IFIN) Business Model
About Cure Pharmaceutical Holding Corp.
What They Do
Develops innovative drug delivery systems.
Business Model
The company focuses on creating advanced drug delivery technologies, such as oral thin films and transdermal systems, which enhance the effectiveness and safety of existing pharmaceuticals. By improving patient adherence and experience, Cure Pharmaceutical generates revenue through partnerships with pharmaceutical firms and commercialization of its proprietary delivery platforms.
Additional Information
Cure Pharmaceutical operates in key therapeutic areas like pain management, oncology, and central nervous system disorders, and aims to address unmet medical needs while promoting personalized medicine.
Company Information
Sector
Technology
Industry
Software - Application
Employees
244
CEO
Mr. King Ong Kong
Country
Singapore
IPO Year
2022
Website
investors.currencgroup.comCure Pharmaceutical Holding Corp. (IFIN) Latest News & Analysis
Latest News
Quick Summary
Seamless Group Inc. and INFINT Acquisition Corp. have completed their business combination. CURRENC Group Inc. will begin trading on Nasdaq under the ticker "CURR" on September 3, 2024.
Why It Matters
CURRENC Group Inc. will begin trading on Nasdaq, signaling potential growth and investment opportunities for fintech sector participants, influencing market dynamics and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
INFINT Acquisition Corp. plans to voluntarily delist its units and Class A shares from NYSE pending the completion of its business combination with Seamless Group Inc.
Why It Matters
Delisting from the NYSE can affect liquidity and access to capital, potentially impacting share value and investor confidence in the business combination with Seamless Group Inc.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
INFINT Acquisition Corporation plans to delist its units and Class A shares from NYSE American after its proposed business combination with Seamless Group Inc. closes.
Why It Matters
Delisting from NYSE American may impact liquidity and investor confidence in INFINT Acquisition Corporation, affecting share value and trading activity post-combination with Seamless Group Inc.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
INFINT Acquisition Corp. received a notification from the NYSE for non-compliance with listing rules due to having fewer than 300 public shareholders. The company has 45 days to submit a compliance plan.
Why It Matters
INFINT Acquisition Corporation faces potential delisting from the NYSE due to insufficient public shareholders, which could impact its stock price and investor confidence significantly.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INFINT ACQUISITION CORPORATION ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
2 years ago
Quick Summary
INFINT Acquisition Corporation (NYSE: IFIN) plans to hold an extraordinary meeting on August 18, 2023, to vote on extending its business combination deadline to February 23, 2024.
Why It Matters
The extension of the business combination deadline allows INFINT Acquisition Corporation more time to secure a deal, potentially increasing its value and reducing liquidation risk for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
INFINT Acquisition Corp. (NYSE: IFIN) plans to extend its business combination deadline to March 23, 2023. Seamless Group will contribute up to $900,000 to support this extension.
Why It Matters
The proposed extension allows INFINT more time to secure a merger with Seamless, potentially stabilizing share value and investor confidence amid uncertainties.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About IFIN Stock
What is Cure Pharmaceutical Holding Corp.'s (IFIN) stock forecast for 2026?
Analyst forecasts for Cure Pharmaceutical Holding Corp. (IFIN) are not currently available. The stock is trading at $3.11.
Is IFIN stock a good investment in 2026?
Analyst ratings for IFIN are not currently available. The stock is currently trading at $3.11. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IFIN stock?
Price predictions from Wall Street analysts for IFIN are not currently available. The stock is trading at $3.11.
What is Cure Pharmaceutical Holding Corp.'s business model?
The company focuses on creating advanced drug delivery technologies, such as oral thin films and transdermal systems, which enhance the effectiveness and safety of existing pharmaceuticals. By improving patient adherence and experience, Cure Pharmaceutical generates revenue through partnerships with pharmaceutical firms and commercialization of its proprietary delivery platforms.
What is the highest forecasted price for IFIN Cure Pharmaceutical Holding Corp.?
Price targets from Wall Street analysts for IFIN are not currently available. The stock is trading at $3.11.
What is the lowest forecasted price for IFIN Cure Pharmaceutical Holding Corp.?
Price targets from Wall Street analysts for IFIN are not currently available. The stock is trading at $3.11.
What is the overall IFIN consensus from analysts for Cure Pharmaceutical Holding Corp.?
Analyst ratings for IFIN are not currently available. The stock is trading at $3.11.
How accurate are IFIN stock price projections?
Stock price projections, including those for Cure Pharmaceutical Holding Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 5, 2026 1:46 AM UTC